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Accurate diagnosis of colorectal cancer
based on histopathology images using
artificial intelligence
K. S. Wang1,2†, G. Yu3†, C. Xu4†, X. H. Meng5†, J. Zhou1,2, C. Zheng1,2, Z. Deng1,2, L. Shang1, R. Liu1, S. Su1, X. Zhou1,
Q. Li1, J. Li1, J. Wang1, K. Ma2, J. Qi2, Z. Hu2, P. Tang2, J. Deng6, X. Qiu7, B. Y. Li7, W. D. Shen7, R. P. Quan7, J. T. Yang7,
L. Y. Huang7, Y. Xiao7, Z. C. Yang8, Z. Li9, S. C. Wang10, H. Ren11,12, C. Liang13, W. Guo14, Y. Li14, H. Xiao15, Y. Gu15,
J. P. Yun16, D. Huang17, Z. Song18, X. Fan19, L. Chen20, X. Yan21, Z. Li22, Z. C. Huang3, J. Huang23, J. Luttrell24,
C. Y. Zhang24, W. Zhou25, K. Zhang26, C. Yi27, C. Wu28, H. Shen6,29, Y. P. Wang6,30, H. M. Xiao7* and H. W. Deng6,7,29*

Abstract
Background: Accurate and robust pathological image analysis for colorectal cancer (CRC) diagnosis is timeconsuming and knowledge-intensive, but is essential for CRC patients’ treatment. The current heavy workload of
pathologists in clinics/hospitals may easily lead to unconscious misdiagnosis of CRC based on daily image analyses.
Methods: Based on a state-of-the-art transfer-learned deep convolutional neural network in artificial intelligence
(AI), we proposed a novel patch aggregation strategy for clinic CRC diagnosis using weakly labeled pathological
whole-slide image (WSI) patches. This approach was trained and validated using an unprecedented and
enormously large number of 170,099 patches, > 14,680 WSIs, from > 9631 subjects that covered diverse and
representative clinical cases from multi-independent-sources across China, the USA, and Germany.
Results: Our innovative AI tool consistently and nearly perfectly agreed with (average Kappa statistic 0.896) and
even often better than most of the experienced expert pathologists when tested in diagnosing CRC WSIs from
multicenters. The average area under the receiver operating characteristics curve (AUC) of AI was greater than that
of the pathologists (0.988 vs 0.970) and achieved the best performance among the application of other AI methods
to CRC diagnosis. Our AI-generated heatmap highlights the image regions of cancer tissue/cells.
(Continued on next page)

* Correspondence: hmxiao@csu.edu.cn; hdeng2@tulane.edu
H.W. Deng is Lead Contact
K.S. Wang, G. Yu, C. Xu, X.H. Meng is Equal first authors
7
Centers of System Biology, Data Information and Reproductive Health,
School of Basic Medical Science, School of Basic Medical Science, Central
South University, Changsha 410008, Hunan, China
6
Department of Deming Department of Medicine, Tulane Center of
Biomedical Informatics and Genomics, Tulane University School of Medicine,
1440 Canal Street, Suite 1610, New Orleans, LA 70112, USA
Full list of author information is available at the end of the article
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.

Wang et al. BMC Medicine

(2021) 19:76

Page 2 of 12

(Continued from previous page)

Conclusions: This first-ever generalizable AI system can handle large amounts of WSIs consistently and robustly
without potential bias due to fatigue commonly experienced by clinical pathologists. It will drastically alleviate the
heavy clinical burden of daily pathology diagnosis and improve the treatment for CRC patients. This tool is
generalizable to other cancer diagnosis based on image recognition.
Keywords: Colorectal cancer, Histopathology image, Deep learning, Cancer diagnosis

Background
Colorectal cancer (CRC) is the third leading cancer by
incidence (6.1%) but second for mortality (9.2%) worldwide [1]. The global burden of CRC is expected to increase 60% by 2030, in terms of new cases and deaths
[2]. The accurate and prompt detection of CRC is essential to improve treatment effectiveness and survivorship.
The current diagnosis of CRC requires an extensive visual examination by highly specialized pathologists. Diagnoses are made using digital whole-slide images (WSIs)
of the hematoxylin and eosin (H&E)-stained specimens
obtained from formalin-fixed paraffin-embedded (FFPE)
or frozen tissues. The challenges for the WSI analysis include very large image size (> 10,000 × 10,000 pixels),
histological variations in size, shape, texture, and staining of nuclei, making the diagnosis complicated and
time-consuming [3]. In most modern pathology departments, the average consultative workload increases by ~
5–10% annually [4]. The current trends indicate a shortage of pathologists around the world, including USA [5]
and low- to middle-income countries [6]. This results in
overworked pathologists, which can lead to higher
chances of deficiencies in their routine work and dysfunctions of the pathology laboratories with more laboratory errors [4]. While the demands of colon
specimen examination in gastroenterology clinics are
high, the training time of pathologists is long (> 10 years)
[7]. It is thus imperative to develop reliable tools for
pathological image analysis and CRC detection that can
improve clinical efficiency and efficacy without unintended human bias during diagnosis.
State-of-the-art artificial intelligence (AI) approaches,
such as deep learning (DL), are very powerful in classification and prediction. There have been many successful
applications of DL, specifically convolutional neural network (CNN), in WSI analysis for lung [8, 9], breast [10,
11], prostate [12–14], and skin [15, 16] cancers. Most of
the existing CNN for the CRC WSI analysis focused on
the pathology work after cancer determination, including
grade classification [17], tumor cell detection and classification [18–20], and survivorship prediction [21–23].
Although they resulted in reasonably high accuracy,
their study sample sizes are limited and do not fully represent the numerous histologic variants of CRC that
have been defined. These variants include tubular,

mucinous, signet ring cell, and others [24]. These limitations inflate prediction error when applied to different
independent samples. Meanwhile, most of the current
DL models were developed from single data source without thorough validation using independent data. They
only calculated the accuracy of patches without diagnosing WSIs or the patients. Their general applicability for
CRC WSI diagnosis in various clinical settings, which
may involve heterogeneous platforms and image properties, remains unclear. A DL approach generalizable to
daily pathological CRC diagnosis that relieves clinical
burden of pathologists and improves diagnostic accuracy
is yet to be developed [25].
Here, we developed a novel automated AI approach
centered on weakly labeled supervised DL for the very
first general clinical application of CRC diagnosis. This
AI approach uses Inception-v3 CNN architecture [26]
with weights initialized from transfer learning. Weakly
labeled supervised learning is advantageous in training
massive and diverse datasets without exact labelling at
object levels (e.g., small cancer cells) [12]. Transfer
learning is a highly effective and efficient DL technique
for image analysis that can utilize previously learned
knowledge on general images for medical image analyses
[27]. Our work is based on WSIs from multiple independent hospitals/sources in China (8554 patients), USA
(1077 patients), and Germany (> 111 slides). This study
has high practical value for improving the effectiveness
and efficiency of CRC diagnosis and thus treatment. It
highlights the general significance and utility of the application of AI to image analyses of other types of
cancers.

Methods
Colorectal cancer whole-slide image dataset

We collected 14,234 CRC WSIs from fourteen independent sources (Table 1). All data were de-identified. The largest image set was from 6876 patients admitted between
2010 and 2018 in Xiangya Hospital (XH), Central South
University (CSU, Changsha, China). XH is the largest hospital in Hunan Province and was established in 1906 with
a close affiliation with Yale University [28]. The other independent sources were The Cancer Genome Atlas
(TCGA) of the USA (https://portal.gdc.cancer.gov/) [29],
the National Centre for Tumor Diseases (NCT) biobank
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Table 1 Usage of datasets from multicenter data source
Data source

Dataset
usage

Sample
Examination Population* CRC
Non-CRC
Total
preparation type
Subjects Slides Subjects Slides Subjects Slides
Radical
surgery/
colonoscopy

Xiangya Hospital (XH)

A

FFPE

100% / 0%

Changsha,
China

614

614

228

228

842

842

NCT-UMM (NCT-CRC-HE-100 K)

B

FFPE

NA

Germany

NA

NA

NA

NA

NA

86

NCT-UMM (CRC-VAL-HE-7 K)

B

FFPE

NA

Germany

NA

NA

NA

NA

NA

25

XH

C

FFPE

80% / 20%

Changsha,
China

3990

7871

1849

2132

5839

10,
003

XH

D

FFPE

89% / 11%

Changsha,
China

98

99

97

114

195

213

Pingkuang Collaborative Hospital
(PCH)

C&D

FFPE

60% / 40%

Jiangxi,
China

50

50

46

46

96

96

The Third Xiangya Hospital of CSU
(TXH)

C&D

FFPE

61% / 39%

Changsha,
China

48

70

48

65

96

135

Hunan Provincial People’s Hospital
(HPH)

C&D

FFPE

61% / 39%

Changsha,
China

49

50

49

49

98

99

ACL

C&D

FFPE

22% / 78%

Changsha,
China

100

100

107

107

207

207

Fudan University Shanghai Cancer
Center (FUS)

C&D

FFPE

97% / 3%

Shanghai,
China

100

100

98

98

198

198

Guangdong Provincial People’s
Hospital (GPH)

C&D

FFPE

77% / 23%

Guangzhou,
China

100

100

85

85

185

185

Nanjing Drum Tower Hospital (NJD)

C&D

FFPE

96% / 4%

Nanjing,
China

100

100

97

97

197

197

Southwest Hospital (SWH)

C&D

FFPE

93% / 7%

Chongqing,
China

99

99

100

100

199

199

The First Affiliated Hospital Air Force
Medical University (AMU)

C&D

FFPE

95% / 5%

Xi’an, China

101

101

104

104

205

205

Sun Yat-Sen University Cancer Center C & D
(SYU)

FFPE

100% / 0%

Guangzhou,
China

91

91

6

6

97

97

Chinese PLA General Hospital (CGH)

C

FFPE

NA

Beijing,
China

0

0

100

100

100

100

TCGA (TCGA-Frozen)

C

Frozen

100% / 0%

U.S.

631

1214

110

133

631**

1347

TCGA (TCGA-FFPE)

C

FFPE

100% / 0%

U.S.

Total

441

441

5

5

446

446

6612

11,
100

3129

3469

9631

14,
680

*
Location map available in Supplementary Text 1.a (see Additional file 1). **For the TCGA –Frozen data only, the non-CRC slides were made with normal intestinal
tissues on part of the CRC slides

and the University Medical Center Mannheim
(UMM) pathology archive (NCT-UMM) of Germany
(https://zenodo.org/record/1214456#.XgaR00dTm00,
[22]), Adicon Clinical Laboratories (ACL), INC, and
eleven hospitals in China (detailed in Table 1). The
hospitals involved are located in the major metropolitan areas of China serving > 139 million population,
including those most prestigious hospitals in pathology in China: XH, Fudan University Shanghai Cancer Center (FUS), Chinese PLA General Hospital
(CGH), Southwest Hospital (SWH), and The First
Affiliated Hospital Air Force Medical University
(AMU); other state-level esteemed hospitals: Sun

Yat-Sen University Cancer Center (SYU), Nanjing
Drum Tower Hospital (NJD), Guangdong Provincial
People’s Hospital (GPH), Hunan Provincial People’s
Hospital (HPH), and The Third Xiangya Hospital of
CSU (TXH); and a regional reputable Pingkuang
Collaborative Hospital (PCH). All WSIs were from
FFPE tissues, except parts (~ 75%) of TCGA WSIs
were from frozen tissues [30]. The process of collection, quality control, and digitalization of the WSIs
is described in Supplementary-Text 1.a (see
Additional file 1).
We formed four datasets (Table 1). Dataset-A includes
slides from only XH and was used for patch-level
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Table 2 Dataset-A (training and testing) and Dataset-B (external validation) for patch-level analysis
Dataset

Cancer

Non-cancer

Total

Subjects

Slides

Patches

Subjects

Slides

Patches

Subjects

Slides

Patches

Training

406

406

19,940

153

153

22,715

559

559

42,655

Testing

208

208

10,116

75

75

10,148

283

283

20,264

Validation

NA

NA

15,550

NA

NA

91,630

NA

111

107,180*

Total

> 614

> 614

45,606

> 228

> 228

124,493

> 842

953

170,099

* There are two datasets used for validation. The number is the sum of the two datasets

training and testing (Table 2). We carefully selected
WSIs to include all common tumor histological subtypes. Using incomplete information of cancer cells/tissues (e.g., location, shape, and demarcation),
pathologists weakly labeled the patches from WSIs as either containing or not cancer cells/tissues. Two weakly
labeled patches were provided as illustrative comparative
examples with two fully labeled patches serving as contrasts (see Additional file 1: Supplementary-Figure 1).
Patches from the same patient were all put into the same
data set (either training or testing) so that the training
and testing data sets are independent. To ensure an appropriate and comprehensive representation of cancer
and normal tissue characteristics, we included an average of 49 patches per tumor sample and 144 patches per
healthy sample. The number of patches containing a
large proportion of cancer cells and the number of
patches containing only a few cancer cells were approximately balanced so that the patches used for training
were representative of cases seen in practice.
Patch-level performance was further validated using
Dataset-B, which contained 107,180 patches downloaded
from NCT-UMM. There were two independent subsets:
100,000 image patches of 86 hematoxylin and eosin stain
(HE) slides of human cancer tissue (NCT-CRC-HE100K) and 7180 image patches of 25 slides of CRC tissue
(CRC-VAL-HE-7K) [22]. The overall split for patch-level
training, testing, and external validation was about 2:1:5.
All images are 224 × 224 pixels at 0.5 μm per pixel. More
description can be found at https://zenodo.org/
record/1214456#.XV2cJeg3lhF. The patches were
rescaled to default input size before they are fed to the
networks for testing.
Dataset-C was used for patient-level validation and is
composed of slides from XH, the other hospitals, ACL, and
frozen and FFPE samples of TCGA. Given the high imbalance of cancer and non-cancer slides in SYU and CGH
(Table 1), they were combined in Dataset-C. In Dataset-C,
the area occupied by cancer cells varied in images from different centers. Most (~ 72%) of the slides from the ten hospitals and ACL contained 10–50% cancer cells by area (see
Additional file 1: Supplementary-Figure 2).
Dataset-D was used for the Human-AI contest and
contained approximately equal number of slides from

XH, the other hospitals, and ACL. There is an average of
~ 5045 patches on each slide, and more than 20% of the
slides contain < 1000 patches. Supplementary-Text 1.b
summarized the allocation of slides in the different datasets (see Additional file 1).
After the slides were digitalized, the visual verification
of the cancer diagnosis labels was performed with high
stringency and accuracy. Dataset-A and Dataset-C included more than 10,000 slides, which were independently reviewed by two senior and seasoned pathologists
with initial and second read. When their diagnoses were
consistent with the previous clinical diagnosis conclusion, the slides were then included in the dataset. If the
two experts disagreed with each other or with the previous clinical diagnosis, the slides were excluded. The labels of slides from TCGA were obtained from the
original TCGA database. The labels of Dataset-B were
from the NCT-UMM. The binary labels of Dataset-D for
the Human-AI contest were more strictly checked.
Three highly experienced senior pathologists independently reviewed the pathological images without knowing
the previous clinical diagnosis. If a consensus was
reached, the slides were included; otherwise, two other
independent pathologists would join the review. After a
discussion among the five pathologists, the sample was
included only if they reached an agreement; otherwise, it
was excluded.
Study design and pipeline

Our approach to predict patient cancerous status involved two major steps: DL prediction for local patches
and patch-level results aggregation for patient-level diagnosis (Fig. 1). The WSIs after preprocessing served as
the input for patch-level prediction. A deep-learning
model was constructed to analyze the patches. The
patch-level prediction was then aggregated by a novel
patch-cluster-based approach to provide slide and
patient-level diagnosis. The performance of patch-level
prediction and the way of aggregation would determine
to a large extent the accuracy of patient-level diagnosis.
Our empirical results showed that a patch-level sensitivity of ~ 95% and specificity of ~ 99% was sufficient to
achieve a high predictive power and control the false
positive rate (FPR) at the patient-level using our
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Fig. 1 Study pipeline and dataset usage

proposed aggregation approach (see Additional file 1:
Supplementary-Text 1.c). In addition, the heatmap and
activation map were generated to show the informative
area on the slide. The details for each step are illustrated
as follows.
Image preprocessing for patch-level training

There were 3 steps in the image preprocessing. First, we
tiled each WSI at × 20 magnification with nonoverlapping 300 × 300 pixel patches, which can be easily
transformed to the required input size of most CNN architectures (such as the 299 × 299 input size required by
Inception-v3 [26], see Additional file 1: SupplementaryTable 1). The use of a smaller patch size compared with
other studies with patches of 512 × 512 pixels would
make the boundaries of cancer regions more accurate
[19]. Second, we removed non-informative background
patches according to two criteria: the maximum difference among the 3 color channel values of the patch was
less than 20, or the brightness of more than 50% of the
patch surface was less than 220 in grayscale [8]. Combining these two criteria, we removed background
patches and kept as many tissue patches as possible.
Third, regular image augmentation procedures were applied, such as random flipping and random adjustment
of the saturation, brightness, contrast, and hue. The
color of each pixel was centered by the mean of each
image and its range was converted/normalized from [0,
255] to [− 1, 1].
Patch-level training by deep learning

Our DL model used Inception-v3 as the CNN architecture to classify cancerous and normal patches. The Inception network uses different kernel sizes and is
specifically powerful in learning diagnostic information
in pathological image from differing scales. This

architecture has achieved near human expert performance in the analyses of other cancer types [8, 15, 31, 32].
There are a few Inception architectures performed well
on the ImageNet dataset [33] and WSIs analysis [33],
such as the Inception-v1 [34], Inception-v3 [26], and
Inception-v4 [35]. We chose Inception-v3 based on extensive comparison of their patch-level and patient-level
performance in testing sets, which showed that the complexity and multiscale modules in Inception-v3 made it
more appropriate to recognize the histopathology WSIs
(see Additional file 1: Supplementary-Text 1.d) [26, 34–
39]. During the study, we also tested some most recent
algorithms, such as DenseNet [37] and ResNeXt [39].
Inception-v3 still performs best at the patch-level CRC
classification.
We initialized the CNN by transfer learning with pretrained weights from ImageNet [26], which were optimized to capture the structures in general images [27].
With transfer learning, our model can recognize pivotal
image features for CRC diagnosis most efficiently. The
300 × 300 pixel patches were resized to a size of 299 ×
299 pixels. Accordingly, the patches in the testing sets
were rescaled to 299 × 299 pixels (0.37 μm/pixels) before
they were fed to the network. The network was deeply
fine-tuned by following training steps. Given the possible
high false positive rate after aggregating the patch-level
results, the optimal set of hyper-parameters was randomly searched with an objective of reaching > 95% sensitivity and > 99% specificity. We showed that, with this
objective at the patch level, the error rate at the patient
level was well controlled (see Additional file 1:
Supplementary-Text 1.c). The network was finalized
after 150,000 epochs of fine-tuning the parameters at all
layers using the RMSProp [40] optimizer with a weight
decay of 0.00004, a momentum value of 0.9, and
RMSProp decay set to 0.9. The initial learning rate was
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0.01 and was exponentially decayed with epochs to the
final learning rate of 0.0001. The optimized result was
achieved when the batch size was 64. The training and
testing procedures were implemented in a Linux server
with an NVIDIA P100 GPU. We used Python v2.7.15
and Tensorflow v1.8.0 for data preprocessing and CNN
model training and testing.
Patient diagnosis and false positive control

Considering the high false positive rate (FPR) accumulated from multiple patch-level predictions, we proposed
a novel patch-cluster-based aggregation method for
slide-level prediction based on the fact that the tumor
cells tend to gather together (especially at × 20 magnification). Motivated by the clustering inference of fMRI
[41], we predicted the WSI as cancer positive if there
were several positive patches topologically connected as
a cluster on the slide (defined by the cluster size), such
as four patches as a square. Otherwise, we predicted the
slide as negative. We tested various cluster sizes and
chose a cluster size of four as the result of an empirically
observed best balance of sensitivity and FPR in the testing dataset (see Additional file 1: Supplementary-Text
1.e). For a patient who had one or multiple slides, denoted by S = {s1, s2, …, sl}, we provided the patient-level
diagnosis D(S) combining the results from all of the patient’s slides: D(S) = D(s1) ∪ D(s2) ∪ … ∪ D(sl), where
D(sl)= 1 or 0 indicated a positive or negative classification of the lth slide respectively. The patient will be diagnosed as having cancer as long as one of the slides
indicates diagnosis.
Human-AI contest

Six pathologists (A-F) with varying experience of 1 to 18
clinical practice years joined the contest (see Additional
file 1: Supplementary-Table 2). The pathologists independently provided a diagnosis specifying cancer or
non-cancer for each patient after reading the WSIs in
Dataset-D. The pathologists did not participate in the
data collection or labeling. An independent analyst
blindly summarized and compared the accuracy and
speed of AI and human experts in performing diagnosis.
Statistical analysis and visualization

We assessed the performance of the AI and pathologists in terms of sensitivity, specificity, and accuracy
correct predictions
( #of
#of total predictions ) for the diagnosis. The receiver operating characteristic (ROC) curve that plotted the
sensitivity versus the FPR and the corresponding
area under the ROC curve (AUC) were computed.
The AUCs of AI and each of the pathologists in
multiple datasets were compared by the paired Wilcoxon signed-rank test. We examined the pairwise
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agreements among AI and pathologists by Cohen’s
Kappa statistic (K). The statistical analyses were
done in R v3.5 (Vienna, Austria), using packages
caret, ggplot2, pROC, and psych among others. Statistical significance level was set at an alpha level of
0.05.
To locate the CRC region in the WSI, we visualized
the WSI as a heatmap based on the confidence score
of each patch. Brighter regions indicate higher confidence that the classifier would consider the region
cancer positive. The heatmap was generated by Python (https://www.python.org/) and overlaid with the
original WSI by gimp (https://www.gimp.org/).

Results
Highest accuracies in patch-level prediction by our model

We divided the 842 WSIs from Dataset-A (Table 1) into
62,919 non-overlapping patches (Table 2) to construct
the CNN for patch-level prediction based on fine-tuning
of Inception-v3. An average of ~ 75 patches per WSI
were included to ensure an appropriate and comprehensive representation of cancer and normal tissue characteristics. Three major CRC histological subtypes were
involved for the training and testing, including 74.76%
tubular, 24.59% mucinous, and 0.65% signet ring cell
patches, roughly reflecting their clinical incidences [42].
In the training, 19,940 (46.75%) patches had cancer, and
22,715 (53.25%) patches were normal. Using another independent set of 10,116 (49.92%) cancer and 10,148
(50.08%) non-cancer patches, the AI for patch-level prediction achieved a testing accuracy of 98.11% and an
AUC of 99.83%. The AUC outperformed that of all the
previous AI studies for CRC diagnosis and prediction
(79.2–99.4%) and even for the majority of other types of
cancer
(82.9–99.9%,
see
Additional
file
1:
Supplementary-Tables 3, [8, 12, 17, 19, 22, 43–48]). The
specificity was 99.22% and the sensitivity 96.99%, both
outstanding. In the external validation Dataset-B, our
model yielded an accuracy and AUC of 96.07% and
98.32% in NCT-CRC-HE-100 K, and 94.76% and 98.45%
in CRC-VAL-HE-7 K, which matched the performance
from in-house data and outplayed the patch-level validation analysis in other AI studies (AUC 69.3–95.0%, see
Additional file 1: Supplementary-Table 3). The patchlevel testing and validation result was summarized in
Table 3.
Diagnosis of CRC at patient level using DL-predicted
patches

Our AI approach was tested for patient diagnosis with
13,514 slides from 8594 patients (Dataset-C). In the largest subset (5839 patients) from XH, our approach produced an accuracy of 99.02% and an AUC of 99.16%
(Fig. 2, Table 3). In other independent multicenter
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Table 3 Patch-level (Dataset-A and Dataset-B) and patient-level
(Dataset-C and Dataset-D) performance summary
Source

Sensitivity

Specificity

Accuracy

AUC

99.22%

98.11%

99.83%

Dataset-A (patch-level testing)
XH

96.99%

Dataset-B (patch-level validation)
NCT-CRC-HE-100 K

92.03%

96.74%

96.07%

98.32%

CRC-VAL-HE-7 K

94.24%

94.87%

94.76%

98.45%

Dataset-C (patient-level validation)
XH

98.80%

99.51%

99.02%

99.16%

TCGA-Frozen

94.04%

88.06%

93.44%

91.05%

TCGA-FFPE

97.96%

100.00%

97.98%

98.98%

SYU-CGH

98.90%

92.45%

95.43%

95.68%

Dataset-D (patient-level Human-AI contest)
XH

97.96%

100%

98.97%

98.99%

SYU

98.90%

100%

98.97%

99.45%

Dataset-C and Dataset-D (patient-level validation and Human-AI
contest)
PCH

96.00%

97.83%

96.88%

97.91%

TXH

100%

97.92%

98.96%

99.20%

HPH

97.96%

97.96%

97.96%

98.98%

FUS

100%

97.96%

98.99%

99.99%

GPH

100%

97.65%

98.91%

99.15%

NJD

92.93%

97.94%

95.41%

95.84%

SWH

98.99%

97.00%

97.99%

99.42%

AMU

97%

97.06%

97.04%

98.37%

ACL

100%

97.20%

98.55%

99.83%

datasets, our approach consistently performed very well.
For the FFPE slides from other hospitals, TCGA-FFPE,
and ACL, the AI approach yielded an average AUC and
accuracy higher than 97.65% (Fig. 2). For frozen slides
TCGA-Frozen, the AI accuracy and AUC were 93.44%
and 91.05% respectively (Fig. 2). Our AUC values (ranging from 91.05 to 99.16%) were higher than that of
other AI-based approaches for independent datasets
(ranging from 83.3 to 94.1%). Of note, because the majority of those earlier AI approaches were tested on datasets of much smaller sample sizes (see Additional file 1:
Supplementary-Table 3), their performances may be
over-estimated. The limited number of negative slides in
TCGA may result in an imbalanced classification problem that needs further investigation, which is beyond the
scope of this study. The results on TCGA-Frozen slides
showed that our method did learn the histological
morphology of cancer and normal tissues for cancer
diagnosis, which is preserved in both the FFPE and frozen samples, even though our method was developed
based on the FFPE samples. Table 3 summarized the
complete patient-level result.
Contest with six human experts

The performance of our AI approach was consistently
comparable to the pathologists in diagnosing 1831 WSIs
from independent centers (Dataset-D, Fig. 3). The AI resulted in an average accuracy and AUC of 98.06% (95%
confidence interval [CI] 97.36 to 98.75%) and 98.83%
(95% CI 98.15 to 99.51%), which both ranked top three
out of the seven competitors (AI plus the six

Fig. 2 Patient-level testing performance on twelve independent datasets from Dataset-C. Left: the radar map of the sensitivity, specificity,
accuracy, and AUC in each dataset from Dataset-C. Right: the boxplot showing the distribution of sensitivity, specificity, accuracy, and AUC in
datasets excluding XH and TCGA. The horizontal bar in the box indicates the median, while the cross indicates the mean. Circles represent
data points
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Fig. 3 ROC analysis of AI and pathologists in the Human-AI contest using Dataset-D. The blue line is the estimated ROC curve for AI. The colored
triangles indicate the sensitivity and specificity achieved by the six pathologists

pathologists) and were greater than the average of the
pathologists (accuracy 97.14% (95% CI 96.12 to 98.15%)
and AUC 96.95% (95% CI 95.74 to 98.16%)). The paired
Wilcoxon signed-rank test of AUCs in multicenter datasets found there were no significant differences between
AI and each of the pathologists. The AI yielded the highest sensitivity (98.16%) relative to the average (97.47%)
of the pathologists (see Additional file 1: SupplementaryTable 4). The pathologists (D and E) who slightly outperformed the AI have 7 and 12 years of clinical experience respectively, while the AI outperformed the other 4
pathologists with 1, 3, 5, and 18 years of experience respectively. Cohen’s Kappa statistic (K) showed an excellent agreement (K ≥ 0.858, average 0.896) between AI
and every pathologist (see Additional file 1:
Supplementary-Table 5). Our approach is thus proven
generalizable to provide diagnosis support for potential
CRC subjects like an independent pathologist, which can
drastically relieve the heavy clinical burden and training
cost of professional pathologists. Details of the HumanAI contest are given in Supplementary-Tables 4 & 5 (see
Additional file 1)
The pathologists were all informed to compete with
our AI and with each other; hence, their performances
were achieved under their best possible conditions with
very best effort, which represented their highest skill
with least error. However, with heavy workload in clinic,
their performance in terms of accuracy and speed will
not be as stable as that of AI. The current study of AI in

cancer diagnosis using WSI has shown that AI can accurately diagnose in ~ 20 s [8] or less (~ 13 s in our case).
With evolved DL techniques and advanced computing
hardware, the AI can constantly improve and provide
steady, swift, and accurate first diagnosis for CRC or
other cancers.
Slide-level heatmap

Our approach offers an additional distinct feature: heatmap for highlighting potential cancer regions (as
patches) in WSI. In Fig. 4, we presented two WSIs,
which were overlaid with the predicted heatmap. For
both radical surgery WSI and colonoscopy WSI, the true
cancerous region was highly overlapped with highlighted
patches obtained by AI, which was also verified by pathologists. See more examples in Supplementary-Figure
3 (see Additional file 1). In addition, to visualize informative regions utilized by DL for the CRC detection, we
provided the activation maps in Supplementary-Figure 4
(see Additional file 1).

Discussion
We collected high-quality, comprehensive, and multiple
independent human WSI datasets for training, testing,
and external validation of our AI-based approach focusing on pathological diagnosis of CRC under common
clinical settings. We mimicked the clinical procedure of
WSI analysis, including the image digitalization, slide review, and expert consultations of the disputed slides.
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Fig. 4 Heatmap produced by AI. Top row: WSI from radical surgery (left) and colonoscopy (right); middle row: AI predicted heatmap
corresponding to the first row, with white coloration indicating predicted cancer region; bottom row: heatmap overlaid on the
corresponding WSI

Different from other studies [21], we did not apply any
manual selection of slides or the area of interest when
building the study dataset. Given the complex histologic
variants of CRC, we randomly selected training patches
from three most commonly seen subtypes roughly proportional to their incidences. The number of patches
from images with large and small cancer tissue area was
balanced and well represented in patch-level analysis.
The collected images were labeled by agreement of at
least two senior experts in CRC pathology (see Additional file 1: Supplementary-Text 1.b). The testing

dataset from different locations in China, USA, and
Germany served as a representative pool for validation
and generalization. Our dataset well represents the slides
seen in clinics. Consequently, the trained AI model is robust and generalizable to analyze images of different
production protocols and image quality.
For a fast-growing area, we are aware of that several
new CNN architectures have been proposed after the
completion of the study of the present paper, such as
the DenseNet [37], Squeeze-and-Excitation network
[38], and ResNeXt [39]. We did some exploratory
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analysis by comparing the ResNet152V2, DenseNet201,
and NASNetLarge relative to the Inception-v3 in classifying patches. DenseNet201 produced similar evaluation
metrics as Inception-v3, while the other two architectures yielded less accuracy and AUC than Inception-v3.
Although these new models have been shown to increase the prediction accuracy on ImageNet dataset
compared to Inception-v3, the complexity (depth and
number of parameters) and the multiscale modules in
Inception-v3 may be appropriate to recognize the CRC
WSIs. The performance of the new architectures on
pathology images analysis and cancer diagnosis deserves
more focused dedicated research for more detailed technical comparison. Moreover, we identify other techniques that may extend the current study, such as the
semi- and unsupervised learning [49, 50], which can
learn from more WSIs with and without labels efficiently, and the multiscale decision aggregation and data
augmentation [51], which can work in the presence of
limited data. Given the highly accurate performance
already achieved in the current approach presented, we
can investigate if and how these new techniques might
attain the current prediction performance with less data
collection and labelling effort in future studies.
There are several histological types that were too rare
(less than 0.5% in incidence [52]) to be included, such as
medullary, micropapillary, and serrated. Our AI approach performed only slightly less satisfactory in frozen
samples than in FFPE samples. With WSIs from rare
types and more frozen samples available for training in
the future, we expect our approach can be constantly
improved to be more generalizable.
Most of the previous studies obtained the patient’s
diagnosis by integrating the patch-level recognition results, since it is not feasible to process the large-size
WSI directly. This strategy is difficult to control the accumulated false positive rate (FPR) from multiple predictions based on individual patches. Recently, Coudray
et al. used the proportion of positive patches or the average probability of all patches as the prediction criterion
for the WSI [8]. Although their results were verified in
three independent datasets (all with small sample sizes
(340 slides)), their aggregation method may not be valid
for those images with only a small area of cancer tissues
where it will yield false negative findings for cancer patients. Instead, we proposed a novel aggregation strategy
for patch-based WSI or patient-level prediction, which is
intuitive and can easily balance the sensitivity and specificity. Specifically, we aggregated information from the
cluster of patches that are topologically connected on
the slide to determine the cancer status. In practice, setting the cluster size to four is most likely to exceed the
average accuracy of pathologists, while cluster size of
two can be used for pathological screening with an
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average sensitivity of ~ 99.78% and an average specificity
of ~ 72.29% according to our test data (see Additional
file 1: Supplementary-Text 1.e).

Conclusions
In summary, we developed a novel AI-based histopathological image classification approach for CRC diagnosis
using deep learning, which achieved the best performance with the largest number of sample sizes and data
sources in the field so far. Our approach was able to
quickly and accurately distinguish CRC cases from
healthy or inflammatory cases and was comparable to or
even superior to pathologists in the testing of large-scale
multicenter data. To the best of our knowledge, this is
the first AI study for a reliable, generalized, and robust
auxiliary tool for daily clinical pathology diagnosis of
CRC initial screening. Our approach may also be
adapted and applied to the histological analysis of other
cancer types via the code available upon request.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12916-021-01942-5.
Additional file 1: Supplementary-Text 1.a Collection and
digitalization of the WSIs. Supplementary-Text 1.b Dataset-A, B, C and
D. Supplementary-Text 1.c Patch-level performance and patient-level
accuracy. Supplementary-Text 1.d Comparison of different
architectures at patch-level. Supplementary-Text 1.e Comparison of
different cluster sizes for aggregation of patch-level results.
Supplementary-Table 1. Input patch size for common CNN.
Supplementary-Table 2 Pathologist info. Supplementary-Table 3 List
of AUCs of AI applied in CRC and other cancer types. SupplementaryTable 4 Overall performance of AI and pathologists in Human-AI contest.
Supplementary-Table 5 Cohen’s Kappa coefficient for agreement
among human experts and AI. Supplementary-Figure 1 Weakly-labeled
and fully-labeled CRC patches. Supplementary-Figure 2.The
distribution of cancerous area in multiple independent WSI datasets
measured by the proportion of patches (P) containing cancer cells on the
WSI. Supplementary-Figure 3 Heatmap produced by AI.
Supplementary-Figure 4 Activation map produced by AI.

Abbreviations
AI: Artificial intelligence; AMU: The First Affiliated Hospital Air Force Medical
University; AUC: Average area under the receiver operating characteristics
curve; CNN: Convolutional neural network; CGH: Chinese PLA General
Hospital; CRC: Colorectal cancer; DL: Deep learning; FFPE: Formalin-fixed
paraffin-embedded; FPR: False positive rate; FUS: Fudan University Shanghai
Cancer Center; GPH: Guangdong Provincial People’s Hospital; HPH: Hunan
Provincial People’s Hospital; H&E: Hematoxylin and eosin; NJD: Nanjing Drum
Tower Hospital; PCH: Pingkuang Collaborative Hospital; SWH: Southwest
Hospital; SYU: Sun Yat-Sen University Cancer Center; TXH: The Third Xiangya
Hospital of CSU; WSI: Whole-slide image; XH: Xiangya Hospital
Acknowledgements
Part of the computing for this project was performed at the OU
Supercomputing Center for Education & Research (OSCER) at the University
of Oklahoma (OU). The authors would like to appreciate the assistance of
Lance Ford, The University of Oklahoma Health Sciences Center, in editing
the manuscript. We thank the editor and the three anonymous reviewers
whose comments/suggestions helped improve and clarify this manuscript.

Wang et al. BMC Medicine

(2021) 19:76

Authors’ contributions
Conceptualization, H.W.D., H.M.X., K.S.W., G.Y., C.X., and X.H.M.; Methodology,
G.Y., K.S.W., X.H.M., C.X., C.Y.Z., J.L., W.Z., K.Z., Y.P.W., S.C.W., Z.C.H., J.H., H.M.X.,
and H.W.D.; Investigation, H.M.X., K.S.W., G.Y., C.X., X.H.M., and H.W.D.;
Writing—original draft, C.X., X.H.M., G. Y, and K.S.W.; Writing—review and
editing, H.W.D., H.M.X., Y.P.W., C.Y.Z., J.L., W.Z., K.Z., C.W., and H.S.; Funding
acquisition, H.M.X., H.W.D., and K.S.W.; Resources, H.M.X., K.S.W., G.Y., and
H.W.D.; Data curation, K.S.W., J.Z., C.Z., Z.D., L.S., R.L., S.S., X.Z., Q.L., J.L., J.W.,
K.M., J.Q., Z.H., P.T., J.D., X.Q., B.Y.L., W.D.S., R.P.Q., J.T.Y., L.Y.H., Y.X., Z.C.Y., Z.L.,
H.R., C.L., W.G., Y.L., H.X., Y.G., J.P.Y., D.H., Z.S., X.F., L.C., X.Y., Z.L., and C.Y.;
Supervision, H.M.X. and H.W.D. The author(s) read and approved the final
manuscript.
Funding
H.S. and H.W.D. were partially supported by grants from National Institutes of
Health (R01AR059781, P20GM109036, R01MH107354, R01MH104680,
R01GM109068, R01AR069055, U19AG055373, R01DK115679), the Edward G.
Schlieder Endowment and the Drs. W. C. Tsai and P. T. Kung Professorship in
Biostatistics from Tulane University. H.M.X. was partially supported by the
National Key Research and Development Plan of China (2017YFC1001103,
2016YFC1201805), National Natural Science Foundation of China
(#81471453), and Jiangwang Educational Endowment. K.S.W. was partially
supported by the National Natural Science Foundation of China (#81972490)
and the Natural Science Foundation of Hunan Province (#2015JJ2150). Z.C.Y.
was partially supported by the National Natural Science Foundation of China
(#81673491). K.Z. was partially supported by grants from National Institutes of
Health (2U54MD007595).
Availability of data and materials
The datasets analyzed during the current study are not publicly available due
to limited computing/storage resources but are available from the
corresponding author on reasonable request. The source code of our
approach is available at GitHub: https://github.com/csu-bme/DeepPathologyCRC.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1
Department of Pathology, Xiangya Hospital, Central South University,
Changsha 410078, Hunan, China. 2Department of Pathology, School of Basic
Medical Science, Central South University, Changsha 410013, Hunan, China.
3
Department of Biomedical Engineering, School of Basic Medical Science,
Central South University, Changsha 410013, Hunan, China. 4Department of
Biostatistics and Epidemiology, The University of Oklahoma Health Sciences
Center, Oklahoma City, OK 73104, USA. 5Laboratory of Molecular and
Statistical Genetics, College of Life Sciences, Hunan Normal University,
Changsha 410081, Hunan, China. 6Department of Deming Department of
Medicine, Tulane Center of Biomedical Informatics and Genomics, Tulane
University School of Medicine, 1440 Canal Street, Suite 1610, New Orleans,
LA 70112, USA. 7Centers of System Biology, Data Information and
Reproductive Health, School of Basic Medical Science, School of Basic
Medical Science, Central South University, Changsha 410008, Hunan, China.
8
Department of Pharmacology, Xiangya School of Pharmaceutical Sciences,
Central South University, Changsha 410078, Hunan, China. 9School of Life
Sciences, Central South University, Changsha 410013, Hunan, China.
10
College of Information Science and Engineering, Hunan Normal University,
Changsha 410081, Hunan, China. 11Department of Pathology, Gongli
Hospital, Second Military Medical University, Shanghai 200135, China.
12
Department of Pathology, the Peace Hospital Affiliated to Changzhi
Medical College, Changzhi 046000, China. 13Pathological Laboratory of
Adicon Medical Laboratory Co., Ltd, Hangzhou 310023, Zhejiang, China.
14
Department of Pathology, First Affiliated Hospital of Hunan Normal
University, The People’s Hospital of Hunan Province, Changsha 410005,
Hunan, China. 15Department of Pathology, the Third Xiangya Hospital,

Page 11 of 12

Central South University, Changsha 410013, Hunan, China. 16Department of
Pathology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.
17
Department of Pathology, Fudan University Shanghai Cancer Center,
Shanghai 200032, China. 18Department of Pathology, Chinese PLA General
Hospital, Beijing 100853, China. 19Department of Pathology, Nanjing Drum
Tower Hospital, the Affiliated Hospital of Nanjing University Medical School,
Nanjing 210008, China. 20Department of Pathology, The first affiliated
hospital, Air Force Medical University, Xi’an 710032, China. 21Institute of
Pathology and southwest cancer center, Southwest Hospital, Third Military
Medical University, Chongqing 400038, China. 22Department of Pathology,
Guangdong Provincial People’s Hospital, Guangdong Academy of Medical
Sciences, Guangzhou 510080, China. 23Department of Anatomy and
Neurobiology, School of Basic Medical Science, Central South University,
Changsha 410013, Hunan, China. 24School of Computing Sciences and
Computer Engineering, University of Southern Mississippi, Hattiesburg, MS
39406, USA. 25College of Computing, Michigan Technological University,
Houghton, MI 49931, USA. 26Department of Computer Science,
Bioinformatics Facility of Xavier NIH RCMI Cancer Research Center, Xavier
University of Louisiana, New Orleans, LA 70125, USA. 27Department of
Pathology, Ochsner Medical Center, New Orleans, LA 70121, USA.
28
Department of Statistics, Florida State University, Tallahassee, FL 32306,
USA. 29Division of Biomedical Informatics and Genomics, Deming
Department of Medicine, Tulane University School of Medicine, New Orleans,
LA 70112, USA. 30Department of Biomedical Engineering, Tulane University,
New Orleans, LA 70118, USA.
Received: 22 October 2020 Accepted: 16 February 2021

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global
patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;
66(4):683–91.
3. Komura D, Ishikawa S. Machine learning methods for histopathological
image analysis. Comput Struct Biotechnol J. 2018;16:34–42.
4. Maung R. Pathologists’ workload and patient safety. Diagnostic Histopathol.
2016;22(8):283–7.
5. Metter DM, Colgan TJ, Leung ST, Timmons CF, Park JY. Trends in the US and
Canadian pathologist workforces from 2007 to 2017. JAMA Netw Open.
2019;2(5):e194337.
6. Sayed S, Lukande R, Fleming KA. Providing pathology support in lowincome countries. J Glob Oncol. 2015;1(1):3–6.
7. Black-Schaffer WS, Morrow JS, Prystowsky MB, Steinberg JJ. Training
pathology residents to practice 21st century medicine: a proposal. Acad
Pathol. 2016;3:2374289516665393.
8. Coudray N, Ocampo PS, Sakellaropoulos T, Narula N, Snuderl M, Fenyo D,
Moreira AL, Razavian N, Tsirigos A. Classification and mutation prediction
from non-small cell lung cancer histopathology images using deep
learning. Nat Med. 2018;24(10):1559–67.
9. Hua K-L, Hsu C-H, Hidayati SC, Cheng W-H, Chen Y-J. Computer-aided
classification of lung nodules on computed tomography images via deep
learning technique. OncoTargets Ther. 2015;8:2015–22.
10. Veta M, van Diest PJ, Willems SM, Wang H, Madabhushi A, Cruz-Roa A,
Gonzalez F, Larsen AB, Vestergaard JS, Dahl AB, et al. Assessment of
algorithms for mitosis detection in breast cancer histopathology images.
Med Image Anal. 2015;20(1):237–48.
11. Ehteshami Bejnordi B, Veta M. Johannes van Diest P, van Ginneken B,
Karssemeijer N, Litjens G, van der Laak J, the CC, Hermsen M, Manson QF
et al: Diagnostic assessment of deep learning algorithms for detection of
lymph node metastases in women with breast cancer. JAMA. 2017;318(22):
2199–210.
12. Campanella G, Hanna MG, Geneslaw L, Miraflor A. Werneck Krauss Silva V,
Busam KJ, Brogi E, Reuter VE, Klimstra DS, Fuchs TJ: Clinical-grade
computational pathology using weakly supervised deep learning on whole
slide images. Nat Med. 2019;25(8):1301–9.
13. Bulten W, Pinckaers H, van Boven H, Vink R, de Bel T, van Ginneken B, van
der Laak J, Hulsbergen-van de Kaa C, Litjens G. Automated deep-learning

Wang et al. BMC Medicine

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.
25.
26.

27.

28.

29.

30.

31.

32.

33.

34.

(2021) 19:76

system for Gleason grading of prostate cancer using biopsies: a diagnostic
study. Lancet Oncol. 2020;21(2):233–41.
Strom P, Kartasalo K, Olsson H. Artificial intelligence for diagnosis and
grading of prostate cancer in biopsies: a population-based, diagnostic study
(vol 21, pg 222, 2020). Lancet Oncol. 2020;21(2):E70.
Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, Thrun S.
Dermatologist-level classification of skin cancer with deep neural networks.
Nature. 2017;542(7639):115–8.
Yu L, Chen H, Dou Q, Qin J, Heng PA. Automated melanoma recognition in
dermoscopy images via very deep residual networks. IEEE Trans Med
Imaging. 2017;36(4):994–1004.
Sari CT, Gunduz-Demir C. Unsupervised feature extraction via deep learning
for histopathological classification of colon tissue images. IEEE Trans Med
Imaging. 2019;38(5):1139–49.
Sirinukunwattana K, Ahmed Raza SE, Yee-Wah T, Snead DR, Cree IA, Rajpoot
NM. Locality sensitive deep learning for detection and classification of
nuclei in routine Colon Cancer histology images. IEEE Trans Med Imaging.
2016;35(5):1196–206.
Haj-Hassan H, Chaddad A, Harkouss Y, Desrosiers C, Toews M, Tanougast C.
Classifications of multispectral colorectal cancer tissues using convolution
neural network. J Pathol Inform. 2017;8:1.
Chaddad A, Tanougast C. Texture analysis of abnormal cell images for
predicting the continuum of colorectal Cancer. Anal Cell Pathol (Amst).
2017;2017:8428102.
Bychkov D, Linder N, Turkki R, Nordling S, Kovanen PE, Verrill C, Walliander
M, Lundin M, Haglund C, Lundin J. Deep learning based tissue analysis
predicts outcome in colorectal cancer. Sci Rep. 2018;8(1):3395.
Kather JN, Krisam J, Charoentong P, Luedde T, Herpel E, Weis C-A, Gaiser T,
Marx A, Valous NA, Ferber D, et al. Predicting survival from colorectal cancer
histology slides using deep learning: a retrospective multicenter study. Plos
Med. 2019;16(1):e1002730.
Skrede OJ, De Raedt S, Kleppe A, Hveem TS, Liestol K, Maddison J,
Askautrud HA, Pradhan M, Nesheim JA, Albregtsen F, et al. Deep learning
for prediction of colorectal cancer outcome: a discovery and validation
study. Lancet. 2020;395(10221):350–60.
Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma:
pathologic aspects. J Gastrointest Oncol. 2012;3(3):153–73.
Algorithms May Assist Expert Pathologists in Prostate Cancer Diagnosis.
Cancer Discov 2020, 10(3):OF1.
Szegedy C, Vanhoucke V, Ioffe S, Shlens J, Wojna Z. Rethinking the
Inception Architecture for Computer Vision. In: 2016 IEEE Conference on
Computer Vision and Pattern Recognition (CVPR): 27–30 June 2016 2016;
2016. p. 2818–26.
Kermany DS, Goldbaum M, Cai W, Valentim CCS, Liang H, Baxter SL,
McKeown A, Yang G, Wu X, Yan F, et al. Identifying medical diagnoses
and treatable diseases by image-based deep learning. Cell. 2018;172(5):
1122–31. e1129
Li LJ, Lu GX. How medical ethical principles are applied in treatment with
artificial insemination by donors (AID) in Hunan, China: effective practice at
the Reproductive and Genetic Hospital of CITIC-Xiangya. J Med Ethics. 2005;
31(6):333–7.
Grossman RL, Heath AP, Ferretti V, Varmus HE, Lowy DR, Kibbe WA, Staudt
LM. Toward a shared vision for cancer genomic data. N Engl J Med. 2016;
375(12):1109–12.
Mobadersany P, Yousefi S, Amgad M, Gutman DA, Barnholtz-Sloan JS,
Velazquez Vega JE, Brat DJ, Cooper LAD. Predicting cancer outcomes from
histology and genomics using convolutional networks. Proc Natl Acad Sci U
S A. 2018;115(13):E2970–9.
Gulshan V, Peng L, Coram M, Stumpe MC, Wu D, Narayanaswamy A,
Venugopalan S, Widner K, Madams T, Cuadros J, et al. Development and
validation of a deep learning algorithm for detection of diabetic retinopathy in
retinal fundus photographs. Accuracy of a deep learning algorithm for
detection of diabetic retinopathy. JAMA. 2016;316(22):2402–10.
Litjens G, Kooi T, Bejnordi BE, Setio AAA, Ciompi F, Ghafoorian M, van der
Laak J, van Ginneken B, Sanchez CI. A survey on deep learning in medical
image analysis. Med Image Anal. 2017;42:60–88.
Khosravi P, Kazemi E, Imielinski M, Elemento O, Hajirasouliha I. Deep
convolutional neural networks enable discrimination of heterogeneous
digital pathology images. EBioMedicine. 2018;27:317–28.
Szegedy C, Wei L, Yangqing J, Sermanet P, Reed S, Anguelov D, Erhan D,
Vanhoucke V, Rabinovich A. Going deeper with convolutions. In: 2015 IEEE

Page 12 of 12

35.

36.
37.

38.

39.

40.
41.
42.
43.

44.

45.
46.

47.

48.

49.

50.

51.

52.

Conference on Computer Vision and Pattern Recognition (CVPR): 7–12 June
2015 2015; 2015. p. 1–9.
Szegedy C, Ioffe S, Vanhoucke V, Alemi AA. Inception-v4, inception-resnet
and the impact of residual connections on learning. In: Thirty-First AAAI
Conference on Artificial Intelligence: 2017; 2017.
Simonyan K, Zisserman A: Very deep convolutional networks for large-scale
image recognition. arXiv preprint arXiv:14091556 2014.
Huang G, Liu Z, Lvd M, Weinberger KQ. Densely Connected Convolutional
Networks. In: 2017 IEEE Conference on Computer Vision and Pattern
Recognition (CVPR): 21–26 July 2017 2017; 2017. p. 2261–9.
Hu J, Shen L, Sun G. Squeeze-and-Excitation Networks. In: 2018 IEEE/CVF
Conference on Computer Vision and Pattern Recognition: 18–23 June 2018
2018; 2018. p. 7132–41.
Veit A, Alldrin N, Chechik G, Krasin I, Gupta A, Belongie S. Learning from
Noisy Large-Scale Datasets with Minimal Supervision. In: 2017 IEEE
Conference on Computer Vision and Pattern Recognition (CVPR): 21–26 July
2017 2017; 2017. p. 6575–83.
GSN H, Swersky K. Lecture 6a Overview of Mini-Batch Gradient Descent.
Lecture Notes Distributed in CSC321 of University of Toronto; 2014.
Heller R, Stanley D, Yekutieli D, Rubin N, Benjamini Y. Cluster-based analysis
of FMRI data. Neuroimage. 2006;33(2):599–608.
Liu T. Diagnostic pathology. 3rd ed. Beijing: People’s Medical Publishing
House; 2013.
Xu Y, Jia Z, Wang LB, Ai Y, Zhang F, Lai M, Chang EI. Large scale tissue
histopathology image classification, segmentation, and visualization via
deep convolutional activation features. BMC Bioinformatics. 2017;18(1):281.
Kainz P, Pfeiffer M, Urschler M. Segmentation and classification of colon
glands with deep convolutional neural networks and total variation
regularization. PeerJ. 2017;5:e3874.
Ponzio F, Macii E, Ficarra E, Di Cataldo S. Colorectal Cancer classification
using deep convolutional networks - an experimental study; 2018.
Cruz-Roa A, Basavanhally A, González F, Gilmore H, Feldman M, Ganesan S,
Shih N, Tomaszewski J, Madabhushi A: Automatic detection of invasive
ductal carcinoma in whole slide images with convolutional neural networks.
In: Medical Imaging 2014: Digital Pathology: 2014: International Society for
Optics and Photonics; 2014:904103.
Araujo T, Aresta G, Castro E, Rouco J, Aguiar P, Eloy C, Polonia A, Campilho
A. Classification of breast cancer histology images using convolutional
neural networks. PLoS One. 2017;12(6):e0177544.
Jannesari M, Habibzadeh M, Aboulkheyr H, Khosravi P, Elemento O,
Totonchi M, Hajirasouliha I. Breast cancer histopathological image
classification: a deep learning approach. In: 2018 IEEE International
Conference on Bioinformatics and Biomedicine (BIBM): 3–6 Dec. 2018 2018;
2018. p. 2405–12.
Feng YQ, Zhang L, Mo J. Deep manifold preserving autoencoder for
classifying breast cancer histopathological images. Ieee Acm T Comput Bi.
2020;17(1):91–101.
Alirezazadeh P, Hejrati B, Monsef-Esfahani A, Fathi A. Representation
learning-based unsupervised domain adaptation for classification of breast
cancer histopathology images. Biocybern Biomed Eng. 2018;38(3):671–83.
Karimi D, Nir G, Fazli L, Black PC, Goldenberg L, Salcudean SE. Deep
learning-based Gleason grading of prostate cancer from histopathology
images-role of multiscale decision aggregation and data augmentation. IEEE
J Biomed Health Inform. 2020;24(5):1413–26.
Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of
tumours of the digestive system. 4th ed. Lyon: International Agency for
Research on Cancer; 2010.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

